NSE · ASTEC
Astec Lifesciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹84 Cr with net profit ₹-19 Cr — a -22.43% net margin, versus -17.85% the period before.
Shareholding
As of 2026-09-30
- Promoter71.96%
- Public24.67%
- FII0.03%
- DII3.34%
19,707 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.83× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pesticides / Agrochemicals - Indian · ranked #11 of 30 by market cap · medians across 26 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| UPL Limited | ₹42,925 Cr | 21.69 | 1.23 | 5.54% | 3.83% |
| PI Industries Ltd. | ₹31,117 Cr | 28.81 | 2.77 | 11.76% | 17.88% |
| Sumitomo Chemical India Ltd. | ₹17,999 Cr | 31.49 | 5.31 | 16.02% | 17.86% |
| Sharda Cropchem Ltd. | ₹5,798 Cr | 9.26 | 1.85 | 21.71% | 11.69% |
| Rallis India Ltd. | ₹3,784 Cr | 16.57 | 1.73 | 8.99% | 6.66% |
| Dhanuka Agritech Ltd. | ₹3,721 Cr | 12.75 | 2.65 | 21.17% | 14.59% |
| NACL Industries Limited | ₹2,726 Cr | 104.85 | 4 | 2.49% | 0.81% |
| Bhagiradha Chemicals & Industries Ltd. | ₹2,528 Cr | 91.98 | 3.63 | 2.6% | 4.53% |
| Bharat Rasayan Ltd. | ₹1,569 Cr | 10.73 | 1.23 | 11.43% | 11.92% |
| Insecticides India Ltd. | ₹1,513 Cr | 12.09 | 1.23 | 11.42% | 6.08% |
| Astec Lifesciences Ltd.(this company) | ₹1,479 Cr | — | 3.79 | -20.72% | -15.12% |
AI analysis
AI-generated · google/gemini-2.5-flashAstec Lifesciences Ltd. is listed with a market capitalization of Rs 1561 Cr. The company reported revenue of Rs 386.93 Cr and an EPS of -68.74. Its book value is Rs 119.36 per share.
Positives
- +Promoter holding is high at 71.97% as of March 31, 2026.
- +No promoter shares are reported as pledged.
Negatives
- −The company has negative earnings per share (EPS) of -68.74.
- −The Return on Equity (ROE) is negative at -44.7%.
- −The Return on Capital Employed (ROCE) is negative at -5.54%.
- −The debt-to-equity ratio is high at 1.74.
- −The company reported a net profit of -7.76 Cr for Mar 2026.
Financial Performance
Astec Lifesciences Ltd. reported a revenue of Rs 386.93 Cr. The company's EPS stands at -68.74. Quarterly results show a revenue of Rs 158.62 Cr for Mar 2026, with a net profit of -7.76 Cr. In the preceding quarter, Dec 2025, revenue was Rs 124.72 Cr and net profit was -15.7 Cr.
Profitability & Returns
The company's Return on Equity (ROE) is -44.7% and Return on Capital Employed (ROCE) is -5.54%. The EPS for the latest period is -68.74. The company has not provided a dividend yield.
Balance Sheet
Astec Lifesciences Ltd. has a debt-to-equity ratio of 1.74. The book value per share is Rs 119.36. The company's market capitalization is Rs 1561 Cr.
Ownership & Pledges
The company has reported no promoter share pledges.
Regulatory & Surveillance
No information regarding surveillance measures has been provided for Astec Lifesciences Ltd. for the reporting period.
Data as of — price: 2026-10-26 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.